Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.

CONCLUSIONS: No safety concerns arose, supporting the favorable benefit-risk profile of RZV.
PMID: 30935742 [PubMed - as supplied by publisher]

Source: Vaccine - March 28, 2019 Category: Allergy & Immunology Authors: López-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, Diez-Domingo J, Heineman TC, Lal H, McElhaney JE, McNeil SA, Yeo W, Tavares-Da-Silva F, ZOE-50/70 Study Group Tags: Vaccine Source Type: research